Big Pharma CEOs assess the BD landscape in biotech: Albert Bourla is staying focused on 2025-2030
One of the big questions for 2022 is whether or not we’ll see movement on the BD front toward more deals and acquisitions after a muted start to the year in M&A. Biotech investors would love to see a few significant buyouts come across to help encourage the beleaguered sector, but Big Pharma has failed to respond beyond a few select product deals.
The primary driver here is the need to add significant new programs that can lead to important approvals in the 2025 to 2030 period. But with the IPO market flattened and a host of public biotechs struggling, will Big Pharma see greater opportunities to spread the hundreds of billions of dollars analysts have tracked in their cash caches?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
